Sabine Tejpar

发表

Evaluation of statistical distance metrics between longitudinal scans for predicting early tumor therapy response

Paul Suetens, Jose George, Kathleen Vunckx, 2012 .

Fuzzy Statistical Unsupervised Learning Based Total Lesion Metabolic Activity Estimation in Positron Emission Tomography Images

Paul Suetens, Jose George, Kathleen Vunckx, 2011, MLMI.

Quantitative comparison of automated PET volume delineation methodologies using simulated tumor lesions

Paul Suetens, Jose George, Kathleen Vunckx, 2011, 2011 IEEE International Symposium on Biomedical Imaging: From Nano to Macro.

Fuzzy Multi-class Statistical Modeling for Efficient Total Lesion Metabolic Activity Estimation from Realistic PET Images

Paul Suetens, Jose George, Kathleen Vunckx, 2012, MICCAI.

SLAC: Statistical total lesion metabolic activity computation by fuzzy unsupervised learning of PET images

Paul Suetens, Jose George, Kathleen Vunckx, 2012, Machine Vision and Applications.

A textural feature based tumor therapy response prediction model for longitudinal evaluation with PET imaging

Paul Suetens, Jose George, Kathleen Vunckx, 2012, 2012 9th IEEE International Symposium on Biomedical Imaging (ISBI).

On using textural information from longitudinal PET scans for predicting tumor response

Paul Suetens, Jose George, Kathleen Vunckx, 2012 .

Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.

Sabine Tejpar, Volker Heinemann, Frank Beier, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor)

Sabine Tejpar, Frans van Roy, Benjamin A Alman, 1999, Oncogene.

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

Sabine Tejpar, Mauro Delorenzi, Dirk Klingbiel, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

KRAS Genotypes and Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab—Reply

Sabine Tejpar, Wendy De Roock, Derek J. Jonker, 2011 .

IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies

Sabine Tejpar, Eva Budinská, Claudio Isella, 2015, Science Translational Medicine.

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.

Sabine Tejpar, N. Normanno, F. Ciardiello, 2011, The Lancet. Oncology.

Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers

Sabine Tejpar, Isabelle Salmon, I. Salmon, 2015, PloS one.

Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia.

Sabine Tejpar, E. Van Cutsem, S. Tejpar, 2007, The Journal of clinical investigation.

Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer

Sabine Tejpar, Eva Budinska, Giovanni D'Ario, 2013, The Journal of pathology.

Overcoming resistance to antiangiogenic therapies.

Sabine Tejpar, Hans Prenen, S. Tejpar, 2012, The oncologist.

Molecular and clinical determinants of survival following relapse after treatment of stage ii-iii colon cancer (cc). results of the translational study on the petacc 3-eortc 40993-sakk 60-00 trial

Sabine Tejpar, Dirk Klingbiel, M. Delorenzi, 2010 .

A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency#

Sabine Tejpar, Mauro Delorenzi, Vlad Popovici, 2012, The Journal of pathology.

BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression

Sabine Tejpar, Stephen McLaughlin, Justin Guinney, 2016, Clinical Cancer Research.

Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data.

Sabine Tejpar, Eva Budinska, Simona Rossi, 2014, Journal of the National Cancer Institute.

Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery

Sabine Tejpar, Levi Garraway, Andrea Bild, 2010, The oncologist.

The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab.

Sabine Tejpar, George Fountzilas, George Kouvatseas, 2013, Clinical colorectal cancer.

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC

Sabine Tejpar, N. Normanno, F. Ciardiello, 2009, Nature Reviews Clinical Oncology.

European perspective for effective cancer drug development

Sabine Tejpar, Denis Lacombe, Daniela Aust, 2014, Nature Reviews Clinical Oncology.

Steps forward for cancer precision medicine

Sabine Tejpar, Jeffrey A. Moscow, John W. M. Martens, 2018, Nature Reviews Drug Discovery.

Biopsies: next-generation biospecimens for tailoring therapy

Sabine Tejpar, Caroline Rousseau, Gerald Batist, 2013, Nature Reviews Clinical Oncology.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Sabine Tejpar, Federico Cappuzzo, Mauro Delorenzi, 2010, The Lancet. Oncology.

Transcription Factor Zic2 Inhibits Wnt/β-Catenin Protein Signaling

Sabine Tejpar, Kris Vleminckx, Jean-Jacques Cassiman, 2011, The Journal of Biological Chemistry.

KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience

Sabine Tejpar, István Láng, Gunnar Folprecht, 2008 .

Biopsies: next-generation biospecimens for tailoring therapy

Sabine Tejpar, Caroline Rousseau, Gerald Batist, 2013, Nature Reviews Clinical Oncology.

Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway.

Lin Lu, Sabine Tejpar, Binsheng Zhao, 2020, Journal of the National Cancer Institute.

Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy

Sabine Tejpar, Bruno Landi, Simona Rossi, 2014, Clinical Cancer Research.

Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer.

Sabine Tejpar, Eva Budinska, Graeme Hodgson, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.